Sirtex Medical: Result 2012

A huge market and a treatment that works is helping Sirtex report strong growth. The 2013 result should be just as impressive.

It was a year of strong growth for liver cancer treatment company Sirtex Medical, with the US business performing particularly well. Dose sales in the US rose 32% as the company’s doctor education program begins paying off. Asia-Pacific growth was also strong, with dose sales up 32% (from a much lower base). Only Europe disappointed, with dose sales of 4%, although improvement is expected. Total dose sales rose 23%, accelerating in the second half of the financial year.


{{ twilioFailed ? 'SMS Code Failed to Send…' : 'SMS Code Sent…' }}

Hi {{ user.FirstName }}

Looks like you've already taken a free trial

Please enter your payment details

We have sent you a code via SMS to {{user.DayPhone}}

please enter this code below to activate your membership

We cannot send you a code via SMS to {{user.DayPhone}}

If you didn't receive SMS code please

SMS code cannot be sent due to: {{ twilioStatus }}

Please select one of the options below:

Looks you are already a member. Please enter your password to proceed

Please untick this box when using a public or shared device

Verify your mobile number to unlock a FREE trial

Please sign up for full access

Updating information

Please wait ...

  • Mastercard
  • Visa

The email address you entered is registered with InvestSMART.

Please login or select "Don't know password"

Please untick this box when using a public or shared device

Register as a new member

(using a different email)

Related Articles